Abstract: The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosilate, and the like.

Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.

Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.

Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.

Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.

Abstract: A hologram laminate is provided with a hologram recording layer in which holograms are recorded, a first bonding layer, a pattern layer having a first region and a second region, and a second bonding layer. The hologram recording layer, the first bonding layer, the pattern layer, and the second bonding layer are laminated in this order. Detaching strength of the first bonding layer is larger than detaching strength of the second bonding layer. The detaching strength of the second bonding layer with respect to the first region and the detaching strength of the second bonding layer with respect to the second region are different.

Abstract: An optical disc of a desired thickness is formed by adhering a stamper substrate 20 to an L0 layer substrate 10. Concave/convex portions to transfer fine concave/convex portions for an L1 layer are formed on one principal plane of the stamper substrate 20. After the fine concave/convex portions for the L1 layer were transferred and formed onto an intermediate layer 32 by the stamper substrate 20, the stamper substrate 20 is adhered to the L0 layer substrate 10.

Abstract: A hologram laminate is provided. The hologram laminate includes a hologram record layer, and a surface protection layer. The hologram record layer is made of a photosensitive material. The surface protection layer is coated on one surface of the hologram record layer. The surface protection layer is made of an energy ray curing resin.

Abstract: An optical disc of a desired thickness is formed by adhering a stamper substrate 20 to an L0 layer substrate 10. Concave/convex portions to transfer fine concave/convex portions for an L1 layer are formed on one principal plane of the stamper substrate 20. After the fine concave/convex portions for the L1 layer were transferred and formed onto an intermediate layer 32 by the stamper substrate 20, the stamper substrate 20 is adhered to the L0 layer substrate 10.

Abstract: A dielectric film is formed over the entire surface of a wafer having a plurality of electrode pads in a manner to expose the electrode pads, a first UBM that is a first metal layer is formed over the electrode pad and the dielectric film, a second UBM that is a second metal layer is formed on the first UBM, and a bump is formed by an electroplating processing over the electrode pad through the first and second UBMs, such that the first UBM is formed to be broader than the bottom area of the bump. In this case, since the first UBM is formed to be broader than the bottom area of the bump, the adhesion supporting force of the bump at the first UBM is increased, and consequently, the adhesion of the bump with the electrode pad through the first UBM can be improved.

Abstract: A dielectric film is formed over the entire surface of a wafer having a plurality of electrode pads in a manner to expose the electrode pads, a first UBM that is a first metal layer is formed over the electrode pad and the dielectric film, a second UBM that is a second metal layer is formed on the first UBM, and a bump is formed by an electroplating processing over the electrode pad through the first and second UBMs, such that the first UBM is formed to be broader than the bottom area of the bump. In this case, since the first UBM is formed to be broader than the bottom area of the bump, the adhesion supporting force of the bump at the first UBM is increased, and consequently, the adhesion of the bump with the electrode pad through the first UBM can be improved.

Abstract: A semiconductor wafer has: first semiconductor chips including a side of the semiconductor wafer; second semiconductor chips formed in an area surrounded by the first semiconductor chips, each of the second semiconductor chips having an integrated circuit and pads electrically connected to the integrated circuit; first bumps formed over each of the first semiconductor chips, at least part of each of the first bumps being formed in a columnar shape; and second bumps formed over the pads, respectively, at least part of each of the second bumps being formed in a columnar shape.

Abstract: A semiconductor wafer has: first semiconductor chips including a side of the semiconductor wafer; second semiconductor chips formed in an area surrounded by the first semiconductor chips, each of the second semiconductor chips having an integrated circuit and pads electrically connected to the integrated circuit; first bumps formed over each of the first semiconductor chips, at least part of each of the first bumps being formed in a columnar shape; and second bumps formed over the pads, respectively, at least part of each of the second bumps being formed in a columnar shape.

Abstract: A compound represented by the formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 independently represent an optionally substituted aromatic group; Q represents an optionally substituted divalent aliphatic hydrocarbon group optionally containing O or S; R.sup.1 represents H, acyl group, etc.; and X represents an electron-withdrawing group, an optionally substituted aromatic group, a group of the formula: ##STR2## wherein R.sup.2 and R.sup.3 independently represent H, acyl group or an optionally substituted hydrocarbon group, etc., etc.; or salts thereof are useful as an excellent anti-neurodegenerative agent.

Abstract: The compound ##STR1## wherein ring A represents a benzene ring;Ar represents an aromatic group;R.sup.1 and R.sup.2 independently represent hydrogen, acyl or hydrocarbon group or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom represent a nitrogen-containing heterocyclic group;m represents an integer of 1 to 6;n represents an integer of 2 to 3;- - - - - represents a single bond or a double bond;X stands for --O-- or --NR.sup.3 -- in which R.sup.3 represents hydrogen, acyl or hydrocarbon group where - - - - - is a single bond or .dbd.N-- where - - - - - is a double bond has excellent GnRH receptor antagonizing activity, calcium antagonizing and monoamine-uptake inhibiting activities and and value as a prophylactic/therapeutic drug for sex hormone-dependent diseases and for central nervous system diseases.

Abstract: A compound of the formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 independently represent an optionally substituted aromatic group; P and Q independently represent a divalent aliphatic hydrocarbon group having at least 2 carbon atoms and optionally having either oxygen or sulfur in the carbon chain; R.sup.1 and R.sup.3 independently represent --CO--R, --CONH--R (R represents a hydrocarbon group or a heterocyclic group) or a hydrocarbon group; R.sup.2 and R.sup.4 independently represent hydrogen or an alkyl group; R.sup.2 and R.sup.4 independently represent hydrogen or an alkyl group; R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4, taken together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic group; and j represents 0 or 1, or a salt thereof, has excellent GnRH-receptor antagonizing activity and is useful as a prophylactic and therapeutic agent for hormone-dependent and other diseases.

Abstract: The compound ##STR1## wherein ring A represents a benzene ring; Ar represents an aromatic group; R.sup.1 and R.sup.2 independently represent hydrogen, acyl or hydrocarbon group or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom represent a nitrogen-containing heterocyclic group; m represents an integer of 1 to 6; n represents an integer of 2 to 3; ----- represents a single bond or a double bond; X stands for --O-- or --NR.sup.3 -- in which R.sup.3 represents hydrogen, acyl or hydrocarbon group where ----- is a single bond or .dbd.N-- where ----- is a double bond has excellent GnRH receptor antagonizing activity, calcium antagonizing and monoamine-uptake inhibiting activities and and value as a prophylactic/therapeutic drug for sex hormone-dependent diseases and for central nervous system diseases.

Abstract: The present invention relates to prevention or treatment a brain edema, an intracranial hemorrhage and a cerebral infarction by administering a pharmaceutically effective amount of a compound or a pharmaceutically acceptable salt thereof, for inhibiting a vascular permeability enhancer, which the compound is of the formula: ##STR1## wherein A is halogen, --X--R.sup.3 in which X is O, S, NH or NHNH, and R.sup.3 is H, acyl, a hydrocarbon group or an aromatic heterocyclic group, or --Y.dbd.R.sup.4 in which Y is N or NHN, and R.sup.4 is a divalent hydrocarbon group, and R.sup.1 is H, halogen, a hydrocarbon group, a heterocyclic group or --Z--R.sup.5 in which Z is O, S or NH, and R.sup.5 is H, a hydrocarbon group or an aromatic heterocyclic group;R.sup.2 is H, halogen, a hydrocarbon group or a heterocyclic group;B is --W--R.sup.6 in which W is CH.sub.2, CO or CS, and R.sup.